News

August 27, 2019September 18, 2019

EU Committee Recommends Orphan Drug Status for Ziopharm’s IL-12 Gene Therapy for Glioblastoma

News

A European Medicines Agency (EMA) committee has recommended orphan drug designation for Ziopharm Oncology‘s interleukin (IL)-12 gene therapy — known as the Controlled IL-12 platform — for the treatment of glioblastoma, a ... Read more

August 27, 2019September 6, 2019

Study Explains Checkpoint Inhibitors’ Efficacy in PD-L1 Negative Tumors

News

Immune checkpoint inhibitors targeting the PD-L1 molecule appear to activate immune cells called natural killer (NK) cells, a new study says. This finding may explain why some tumors are responsive ... Read more

August 23, 2019

NKTR-214 with Opdivo Earns FDA’s Breakthrough Therapy Designation for Advanced Melanoma

News

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation for a combination of the potential therapy NKTR-214 with Opdivo (nivolumab) for untreated melanoma patients with either metastatic disease or who ... Read more

August 21, 2019

Esophagogastric Cancer Patients with High DKK1 Levels Respond Better to DKN-01, Keytruda Combo, Phase 1 Trial Shows

News

A combination of Leap Therapeutics‘ investigational therapy DKN-01 plus Keytruda (pembrolizumab) led to “highly encouraging” responses and survival outcomes in a population of advanced esophagogastric cancer patients with elevated levels of ... Read more

August 20, 2019

INmune Bio Shares Early Results of Phase 1 Trial of INB03 for Advanced Cancer Treatment

News

INmune Bio’s therapy candidate INB03 is well-tolerated and has shown signs of activity in patients with advanced cancers, according to preliminary findings from a Phase 1 clinical trial. The early results ... Read more

August 16, 2019September 4, 2019

ADXS-NEO Provoked Strong Immune Response in Advanced Cancer Patient, Early Trial Data Show

News

ADXS-NEO, an investigational cancer immunotherapy, induced an immune response against 90% of all cancer targets in a patient with metastatic microsatellite stable colorectal cancer (MSS-CRC), data from an ongoing Phase ... Read more

August 14, 2019

Tecentriq with Chemo Shows Promise in Untreated Advanced Urothelial Cancer

News

Adding Tecentriq (atezolizumab) to standard chemotherapy reduced the risk of disease worsening or death in previously untreated patients with locally advanced or metastatic urothelial cancer, according to early results of a ... Read more

August 13, 2019

Trial Testing Potential Cancer Therapy THOR-707 Starts Dosing in Australia, Cleared to Enroll in U.S.

News

A Phase 1/2 trial testing the advanced tumors treatment candidate THOR-707 has begun dosing patients in Australia — and has been cleared by the U.S. Food and Drug Administration to ... Read more

August 9, 2019

Upcoming Phase 2 Trial Will Test Opdivo-MTG201 Combo for Malignant Pleural Mesothelioma

News

An upcoming Phase 2 trial will explore the safety and effectiveness of a combo therapy — Opdivo (nivolumab) and MTG201 – for the treatment of malignant pleural mesothelioma. The trial ... Read more

August 7, 2019

Phase 1b Trial of Cabometyx-Tecentriq Combo in Solid Cancers Adding More Patients, Tumor Types

News

Two initial patient groups have been expanded and four others added to a Phase 1b trial assessing the combination therapy Cabometyx (cabozantinib) and Tecentriq (atezolizumab) in people with locally advanced or metastatic solid ... Read more